Common use of Royalty Reports Clause in Contracts

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] of each year Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number “License Agreement between UC SAN DIEGO and SutroVax, Inc. for case SD2012-011. Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] of each year ]. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country;: (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), sales and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees Fees and royalties (“Sublicense Revenues”) received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has Revenues have been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number “License Agreement between UC SAN DIEGO and SutroVax, Inc. for case SD2012-011. number: [***] Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] February 28 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVaxCreative Medical Technology, Inc. for case SD2012SD2005-011. 041.” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEEoxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual [***] royalty reports on or before [***] of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO and SutroVaxOxitope, Inc. for case SD2012SD2005-011. 037.” Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] each February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s 's (and each Affiliate’s 's and Sublicensee’s's) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.12 (Net Sales), and Net Sales (using best efforts for the portion of Net Sales due to Sublicensee and Affiliates) during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold, specifically including the number of Speaker Arrays,; (iv) Sublicense fees Fees and royalties received during the most recently completed calendar year quarter in US dollars, payable with respect thereto, the method used to calculate such Sublicense Fees and royalties, and the names of Sublicensees not introduced by UNIVERSITY; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph Section 4.1(b) should be marked with the following title and case number “number: "License Agreement between UC SAN DIEGO UCSD and SutroVaxComIkar, Inc. for case SD20122010-011. 350." Reports shall be submitted as an attachment to UC SAN DIEGO’s UCSD's email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] each February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b4.1(a) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. TearLab for case SD2012SD2002-011. 180.” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEEoxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, aggregate deductions as provided in Paragraph 1.4 1.6 (Net Sales), and the Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees Fees and royalties received from Sublicensees during the most recently completed calendar year in US dollars, and amounts payable with respect theretothereto pursuant to Paragraph 3.1(d); (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has Fees have been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO and SutroVax, Inc. Theia for case SD2012-011. [**].” Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the worldTerritory, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each countrycountry in the Territory; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.16 (Net Sales), and Net Sales during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees Fees and royalties received during the most recently completed calendar year quarter in US dollars, and the portion thereof payable with respect theretoto UNIVERSITY hereunder; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue Sublicensing Revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph Section 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. Navidea Biopharmaceuticals for case SD2012SD 1998-011088”. Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] each February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.12 (Net Sales), and Net Sales during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year quarter in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVaxOncternal Therapeutics, Inc. for case SD2012SD2015-011. 143.” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] February 28 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.7 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph Section 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVaxUCSD and Palisade Bio, Inc. Inc., for case SD2012-011. [***].” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] February 28 of each year year. Each royalty report shall cover LICENSEE’s 's (and each Affiliate’s 's and Sublicensee’s's) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, . payable with respect thereto; (iii) the number of each type of Licensed Product sold;: (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number “number: "License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. Global Cancer Technology for case SD2012SD2013-011. 199." Reports shall be submitted as an attachment to UC SAN DIEGO’s UCSD's email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] each February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.6 (Net Sales), and Net Sales during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year quarter in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph Section 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. Leading Biosciences for case SD2012-011. […***…].” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: […***…]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the worldTerritory, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each countrycountry in the Territory; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.10 (Net Sales), and Net Sales during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees Fees and royalties received during the most recently completed calendar year quarter in US dollars, and the portion thereof payable with respect theretoto UNIVERSITY hereunder; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue Sublicensing Revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph Section 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. Navidea Biopharmaceuticals for case SD2012SD1998-011088”. Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] February 28 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. <LICENSEE NAME> for case SD2012<XXXX-011. XXX>.” Reports shall be submitted as an attachment to UC SAN DIEGOUCSD’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] February 28 of each year year. Each royalty report shall cover LICENSEE’s 's (and each Affiliate’s 's and Sublicensee’s's) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number “number: "License Agreement between UC SAN DIEGO UCSD and SutroVax, Inc. NanoMed Tracking for case SD2012SD2008-011. 171." Reports shall be submitted as an attachment to UC SAN DIEGO’s UCSD's email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual quarterly royalty reports on or before [***] each February 28, May 31, August 31 and November 30 of each year year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year quarter and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 1.13 (Net Sales), and Net Sales during the most recently completed calendar year quarter and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees and royalties received during the most recently completed calendar year quarter in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) royalties and the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number number: “License Agreement between UC SAN DIEGO and SutroVaxOncternal Therapeutics, Inc. for case SD2012all the cases included in UC Agreement Control No. 2024-011. 0966.” Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEExxx-xxxxxxx@xxxx.xxx.

Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY annual royalty reports on or before [***] of each year ]. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar year and shall show: (i) the date of first commercial sale of a Licensed Product in each country; (ii) the gross sales, deductions as provided in Paragraph 1.4 (Net Sales), and Net Sales during the most recently completed calendar year and the royalties, in US dollars, payable with respect thereto; (iii) the number of each type of Licensed Product sold; (iv) Sublicense fees Fees and royalties received during the most recently completed calendar year in US dollars, payable with respect thereto; (v) the method used to calculate the royalties; and (vi) the exchange rates used. If no sales of Licensed Products have been made and no Sublicense revenue has Fees have been received by LICENSEE during any reporting period, LICENSEE shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number “License Agreement between UC SAN DIEGO and SutroVax, Inc. for case SD2012-011. number: [***] Reports shall be submitted as an attachment to UC SAN DIEGO’s email address: [***]. Such reports and information contained therein shall be deemed confidential information of LICENSEE.